These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 37603207)

  • 1. The efficacy and safety of selective RET inhibitors in RET fusion-positive non-small cell lung cancer: a meta-analysis.
    Ke JY; Huang S; Jing ZT; Duan MC
    Invest New Drugs; 2023 Oct; 41(5):768-776. PubMed ID: 37603207
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pralsetinib in RET fusion-positive non-small-cell lung cancer: A real-world data (RWD) analysis from the Italian expanded access program (EAP).
    Passaro A; Russo GL; Passiglia F; D'Arcangelo M; Sbrana A; Russano M; Bonanno L; Giusti R; Metro G; Bertolini F; Grisanti S; Carta A; Cecere F; Montrone M; Massa G; Perrone F; Simionato F; Guaitoli G; Scotti V; Genova C; Lugini A; Bonomi L; Attili I; de Marinis F
    Lung Cancer; 2022 Dec; 174():118-124. PubMed ID: 36379124
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An overview of the role of selpercatinib and pralsetinib in RET-fusion-positive non-small cell lung cancer (NSCLC).
    Nguyen VQ; Geirnaert M
    J Oncol Pharm Pract; 2023 Mar; 29(2):450-456. PubMed ID: 36572992
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer including as first-line therapy: update from the ARROW trial.
    Griesinger F; Curigliano G; Thomas M; Subbiah V; Baik CS; Tan DSW; Lee DH; Misch D; Garralda E; Kim DW; van der Wekken AJ; Gainor JF; Paz-Ares L; Liu SV; Kalemkerian GP; Houvras Y; Bowles DW; Mansfield AS; Lin JJ; Smoljanovic V; Rahman A; Kong S; Zalutskaya A; Louie-Gao M; Boral AL; Mazières J
    Ann Oncol; 2022 Nov; 33(11):1168-1178. PubMed ID: 35973665
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selpercatinib in RET fusion-positive non-small-cell lung cancer (SIREN): a retrospective analysis of patients treated through an access program.
    Illini O; Hochmair MJ; Fabikan H; Weinlinger C; Tufman A; Swalduz A; Lamberg K; Hashemi SMS; Huemer F; Vikström A; Wermke M; Absenger G; Addeo A; Banerji S; Calles A; Clarke S; Di Maio M; Durand A; Duruisseaux M; Itchins M; Kääränien OS; Krenn F; Laack E; de Langen AJ; Mohorcic K; Pall G; Passaro A; Prager G; Rittmeyer A; Rothenstein J; Schumacher M; Wöll E; Valipour A
    Ther Adv Med Oncol; 2021; 13():17588359211019675. PubMed ID: 34178121
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanisms of resistance to selective RET tyrosine kinase inhibitors in RET fusion-positive non-small-cell lung cancer.
    Lin JJ; Liu SV; McCoach CE; Zhu VW; Tan AC; Yoda S; Peterson J; Do A; Prutisto-Chang K; Dagogo-Jack I; Sequist LV; Wirth LJ; Lennerz JK; Hata AN; Mino-Kenudson M; Nardi V; Ou SI; Tan DS; Gainor JF
    Ann Oncol; 2020 Dec; 31(12):1725-1733. PubMed ID: 33007380
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-world outcomes of chemoimmunotherapy and selective RET inhibitors in Chinese patients with RET fusion-positive non-small cell lung cancer.
    Wan R; Li W; Wang Z; Zhong J; Lin L; Duan J; Wang J
    Heliyon; 2024 Jan; 10(2):e24796. PubMed ID: 38304763
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of selpercatinib in Chinese patients with advanced
    Lu S; Cheng Y; Huang D; Sun Y; Wu L; Zhou C; Guo Y; Shao J; Zhang W; Zhou J
    Ther Adv Med Oncol; 2022; 14():17588359221105020. PubMed ID: 35923928
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selpercatinib in Patients With
    Drilon A; Subbiah V; Gautschi O; Tomasini P; de Braud F; Solomon BJ; Shao-Weng Tan D; Alonso G; Wolf J; Park K; Goto K; Soldatenkova V; Szymczak S; Barker SS; Puri T; Bence Lin A; Loong H; Besse B
    J Clin Oncol; 2023 Jan; 41(2):385-394. PubMed ID: 36122315
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The budget impact of adding pralsetinib to a US health plan formulary for treatment of non-small cell lung cancer and thyroid cancer with
    Duff S; Bargiacchi F; Norregaard C; Brener M; Sullivan E
    J Manag Care Spec Pharm; 2022 Feb; 28(2):218-231. PubMed ID: 34726500
    [No Abstract]   [Full Text] [Related]  

  • 11. Selpercatinib: A Review in Advanced RET Fusion-Positive NSCLC.
    Nie T; Syed YY
    Target Oncol; 2023 Jan; 18(1):169-176. PubMed ID: 36422787
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of Selpercatinib in
    Drilon A; Oxnard GR; Tan DSW; Loong HHF; Johnson M; Gainor J; McCoach CE; Gautschi O; Besse B; Cho BC; Peled N; Weiss J; Kim YJ; Ohe Y; Nishio M; Park K; Patel J; Seto T; Sakamoto T; Rosen E; Shah MH; Barlesi F; Cassier PA; Bazhenova L; De Braud F; Garralda E; Velcheti V; Satouchi M; Ohashi K; Pennell NA; Reckamp KL; Dy GK; Wolf J; Solomon B; Falchook G; Ebata K; Nguyen M; Nair B; Zhu EY; Yang L; Huang X; Olek E; Rothenberg SM; Goto K; Subbiah V
    N Engl J Med; 2020 Aug; 383(9):813-824. PubMed ID: 32846060
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expanded Access Program Pralsetinib in Advanced Non-Small Cell Lung Cancer with Rearranged during Transfection (RET) Gene Rearrangement.
    Jeon Y; Jung HA; Park S; Sun JM; Ahn JS; Ahn MJ; Park K; Lee SH
    Cancer Res Treat; 2023 Oct; 55(4):1144-1151. PubMed ID: 37218138
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pralsetinib: A Review in Advanced RET Fusion-Positive NSCLC.
    Syed YY
    Drugs; 2022 May; 82(7):811-816. PubMed ID: 35587858
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Treatment Status of Patients in NSCLC With RET Fusion Under the Prelude of Selective RET-TKI Application in China: A Multicenter Retrospective Research.
    Meng Y; Yang Y; Fang Y; Lin X; Xie X; Deng H; Wu J; Zhou M; Sun N; Xie Z; Liu M; Ouyang M; Qin Y; Su C; Zhou C
    Front Oncol; 2022; 12():864367. PubMed ID: 35692799
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intracranial Efficacy of Selpercatinib in
    Subbiah V; Gainor JF; Oxnard GR; Tan DSW; Owen DH; Cho BC; Loong HH; McCoach CE; Weiss J; Kim YJ; Bazhenova L; Park K; Daga H; Besse B; Gautschi O; Rolfo C; Zhu EY; Kherani JF; Huang X; Kang S; Drilon A
    Clin Cancer Res; 2021 Aug; 27(15):4160-4167. PubMed ID: 34088726
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Case report: First evidence of impressive efficacy of modulated dose selpercatinib in a young Caucasian with ANK3-RET fusion-positive NSCLC.
    De Carlo E; Bertoli E; Schiappacassi M; Stanzione B; Del Conte A; Doliana R; Spina M; Bearz A
    Front Oncol; 2024; 14():1307458. PubMed ID: 38420011
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of pralsetinib in patients with advanced RET fusion-positive non-small cell lung cancer.
    Zhou Q; Zhao J; Chang J; Wang H; Fan Y; Wang K; Wu G; Nian W; Sun Y; Sun M; Wang X; Shi H; Zheng X; Yao S; Qin M; Shen Z; Yang J; Wu YL
    Cancer; 2023 Oct; 129(20):3239-3251. PubMed ID: 37282666
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of immunotherapy in
    Peng Z; Ding K; Xie M; Xu Y
    Heliyon; 2024 Jul; 10(14):e34626. PubMed ID: 39149080
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pralsetinib for the treatment of a
    Meng Y; Li L; Wang H; Chen X; Yue Y; Wang M; Meng L; Li B; Li X
    Ann Transl Med; 2022 Apr; 10(8):496. PubMed ID: 35571397
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.